CO2021000051A2 - Guías modificadas de arn para edición génica - Google Patents
Guías modificadas de arn para edición génicaInfo
- Publication number
- CO2021000051A2 CO2021000051A2 CONC2021/0000051A CO2021000051A CO2021000051A2 CO 2021000051 A2 CO2021000051 A2 CO 2021000051A2 CO 2021000051 A CO2021000051 A CO 2021000051A CO 2021000051 A2 CO2021000051 A2 CO 2021000051A2
- Authority
- CO
- Colombia
- Prior art keywords
- gene editing
- modified rna
- guidelines
- abstract
- vitro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
RESUMEN Esta divulgación se relaciona con guías modificadas de ARN que tienen actividad mejorada in vitro e in vivo en métodos de edición génica.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862682820P | 2018-06-08 | 2018-06-08 | |
US201862682838P | 2018-06-08 | 2018-06-08 | |
PCT/US2019/036160 WO2019237069A1 (en) | 2018-06-08 | 2019-06-07 | Modified guide rnas for gene editing |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2021000051A2 true CO2021000051A2 (es) | 2021-01-18 |
Family
ID=68770688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2021/0000051A CO2021000051A2 (es) | 2018-06-08 | 2021-01-06 | Guías modificadas de arn para edición génica |
Country Status (15)
Country | Link |
---|---|
US (1) | US20210087568A1 (es) |
EP (1) | EP3802828A4 (es) |
JP (1) | JP2021526804A (es) |
KR (1) | KR20210029772A (es) |
CN (1) | CN112567036A (es) |
AU (1) | AU2019282824A1 (es) |
BR (1) | BR112020024731A2 (es) |
CA (1) | CA3102950A1 (es) |
CO (1) | CO2021000051A2 (es) |
IL (1) | IL278822A (es) |
MX (1) | MX2020013293A (es) |
PH (1) | PH12020552100A1 (es) |
SG (1) | SG11202011539VA (es) |
TW (1) | TW202016306A (es) |
WO (1) | WO2019237069A1 (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7458785B2 (ja) | 2017-01-23 | 2024-04-01 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒドロキシステロイド17-βデヒドロゲナーゼ13(HSD17B13)バリアント及びその使用 |
US11479802B2 (en) | 2017-04-11 | 2022-10-25 | Regeneron Pharmaceuticals, Inc. | Assays for screening activity of modulators of members of the hydroxy steroid (17-beta) dehydrogenase (HSD17B) family |
EP3652312A1 (en) | 2017-07-14 | 2020-05-20 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
EP3585159A1 (en) | 2017-07-31 | 2020-01-01 | Regeneron Pharmaceuticals, Inc. | Cas-transgenic mouse embryonic stem cells and mice and uses thereof |
BR112020001996A2 (pt) | 2017-07-31 | 2020-08-18 | Regeneron Pharmaceuticals, Inc. | animal não humano, e, métodos para testar e para otimizar a capacidade de uma crispr/cas nuclease de excisar um ácido nucleico genômico in vivo, para testar a recombinação induzida por crispr/cas de um ácido nucleico genômico com um ácido nucleico de doador exógeno in vivo e para otimizar a capacidade de crispr/cas de induzir a recombinação de um ácido nucleico genômico com um ácido nucleico de doador exógeno in vivo. |
JP7139419B2 (ja) | 2017-09-29 | 2022-09-20 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化ttr遺伝子座を含む非ヒト動物および使用方法 |
US10961583B2 (en) | 2017-10-11 | 2021-03-30 | Regeneron Phramaceuticals, Inc. | Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation |
CN111885915B (zh) | 2018-03-19 | 2023-04-28 | 瑞泽恩制药公司 | 使用crispr/cas系统对动物进行转录调制 |
WO2020198697A1 (en) * | 2019-03-28 | 2020-10-01 | Intellia Therapeutics, Inc. | Compositions and methods comprising a ttr guide rna and a polynucleotide encoding an rna-guided dna binding agent |
CA3137761A1 (en) | 2019-06-04 | 2020-12-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use |
EP3796776A1 (en) | 2019-06-07 | 2021-03-31 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized albumin locus |
US20220290132A1 (en) * | 2019-08-06 | 2022-09-15 | The Penn State Research Foundation | Engineered CRISPR/Cas9 Systems for Simultaneous Long-term Regulation of Multiple Targets |
CN115176001A (zh) * | 2019-12-11 | 2022-10-11 | 因特利亚治疗公司 | 用于基因编辑的修饰的引导rna |
AU2021396403A1 (en) | 2020-12-11 | 2023-06-29 | Intellia Therapeutics, Inc. | Compositions and methods for reducing mhc class ii in a cell |
IL303506A (en) | 2020-12-11 | 2023-08-01 | Intellia Therapeutics Inc | Polynucleotides, compounds and methods for genome editing involving deamination |
CA3205042A1 (en) | 2020-12-23 | 2022-06-30 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying ciita in a cell |
WO2022140586A2 (en) | 2020-12-23 | 2022-06-30 | Intellia Therapeutics, Inc. | Compositions and methods for reducing hla-a in a cell |
CN117098840A (zh) | 2021-02-08 | 2023-11-21 | 因特利亚治疗公司 | 用于免疫疗法的自然杀伤细胞受体2b4组合物和方法 |
CN117042794A (zh) | 2021-02-08 | 2023-11-10 | 因特利亚治疗公司 | 用于免疫疗法的t细胞免疫球蛋白和粘蛋白结构域3(tim3)组合物和方法 |
EP4288088A2 (en) | 2021-02-08 | 2023-12-13 | Intellia Therapeutics, Inc. | Lymphocyte activation gene 3 (lag3) compositions and methods for immunotherapy |
WO2023028471A1 (en) | 2021-08-24 | 2023-03-02 | Intellia Therapeutics, Inc. | Programmed cell death protein 1 (pd1) compositions and methods for cell-based therapy |
WO2023081687A1 (en) * | 2021-11-03 | 2023-05-11 | Intellia Therapeutics, Inc. | Modified guide rnas for gene editing |
WO2023081200A2 (en) | 2021-11-03 | 2023-05-11 | Intellia Therapeutics, Inc. | Cd38 compositions and methods for immunotherapy |
WO2023185697A2 (en) * | 2022-03-29 | 2023-10-05 | Accuredit Therapeutics (Suzhou) Co., Ltd. | Compositions and methods for treatment of transthyretin amyloidosis |
CN114574598B (zh) * | 2022-04-02 | 2023-08-08 | 中国农业科学院北京畜牧兽医研究所 | 鉴定或辅助鉴定猪5/6肋眼肌面积的方法 |
WO2023245141A2 (en) * | 2022-06-15 | 2023-12-21 | Beam Therapeutics Inc. | Compositions and methods for reducing complement activation |
TW202408595A (zh) | 2022-06-16 | 2024-03-01 | 美商英特利亞醫療公司 | 用於對細胞進行遺傳修飾之方法及組合物 |
TW202409271A (zh) | 2022-06-16 | 2024-03-01 | 美商英特利亞醫療公司 | 用於減少細胞中之mhc 1類之組成物及方法 |
WO2024006955A1 (en) | 2022-06-29 | 2024-01-04 | Intellia Therapeutics, Inc. | Engineered t cells |
WO2024003810A1 (en) * | 2022-06-30 | 2024-01-04 | Geneditbio Limited | Guide rna with chemical modifications |
CN117925623B (zh) * | 2024-03-20 | 2024-06-07 | 北京引正基因科技有限公司 | 用于hao1基因编辑和治疗ph1的组合物 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150376587A1 (en) * | 2014-06-25 | 2015-12-31 | Caribou Biosciences, Inc. | RNA Modification to Engineer Cas9 Activity |
US10513711B2 (en) * | 2014-08-13 | 2019-12-24 | Dupont Us Holding, Llc | Genetic targeting in non-conventional yeast using an RNA-guided endonuclease |
US10900034B2 (en) * | 2014-12-03 | 2021-01-26 | Agilent Technologies, Inc. | Guide RNA with chemical modifications |
EP3280803B1 (en) * | 2015-04-06 | 2021-05-26 | The Board of Trustees of the Leland Stanford Junior University | Chemically modified guide rnas for crispr/cas-mediated gene regulation |
US11279928B2 (en) * | 2015-06-29 | 2022-03-22 | Massachusetts Institute Of Technology | Compositions comprising nucleic acids and methods of using the same |
EP3159407A1 (en) * | 2015-10-23 | 2017-04-26 | Silence Therapeutics (London) Ltd | Guide rnas, methods and uses |
WO2017136794A1 (en) * | 2016-02-03 | 2017-08-10 | Massachusetts Institute Of Technology | Structure-guided chemical modification of guide rna and its applications |
WO2017173054A1 (en) * | 2016-03-30 | 2017-10-05 | Intellia Therapeutics, Inc. | Lipid nanoparticle formulations for crispr/cas components |
-
2019
- 2019-06-07 EP EP19814154.1A patent/EP3802828A4/en active Pending
- 2019-06-07 SG SG11202011539VA patent/SG11202011539VA/en unknown
- 2019-06-07 MX MX2020013293A patent/MX2020013293A/es unknown
- 2019-06-07 KR KR1020217000460A patent/KR20210029772A/ko unknown
- 2019-06-07 BR BR112020024731-6A patent/BR112020024731A2/pt unknown
- 2019-06-07 AU AU2019282824A patent/AU2019282824A1/en active Pending
- 2019-06-07 JP JP2020567951A patent/JP2021526804A/ja active Pending
- 2019-06-07 CA CA3102950A patent/CA3102950A1/en active Pending
- 2019-06-07 CN CN201980052704.4A patent/CN112567036A/zh active Pending
- 2019-06-07 WO PCT/US2019/036160 patent/WO2019237069A1/en active Application Filing
- 2019-06-10 TW TW108120005A patent/TW202016306A/zh unknown
-
2020
- 2020-11-18 IL IL278822A patent/IL278822A/en unknown
- 2020-12-04 US US17/111,769 patent/US20210087568A1/en active Pending
- 2020-12-07 PH PH12020552100A patent/PH12020552100A1/en unknown
-
2021
- 2021-01-06 CO CONC2021/0000051A patent/CO2021000051A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN112567036A (zh) | 2021-03-26 |
JP2021526804A (ja) | 2021-10-11 |
MX2020013293A (es) | 2021-05-12 |
TW202016306A (zh) | 2020-05-01 |
US20210087568A1 (en) | 2021-03-25 |
PH12020552100A1 (en) | 2021-08-02 |
AU2019282824A1 (en) | 2021-01-07 |
KR20210029772A (ko) | 2021-03-16 |
BR112020024731A2 (pt) | 2021-03-23 |
CA3102950A1 (en) | 2019-12-12 |
SG11202011539VA (en) | 2020-12-30 |
WO2019237069A1 (en) | 2019-12-12 |
EP3802828A4 (en) | 2022-10-26 |
IL278822A (en) | 2021-01-31 |
EP3802828A1 (en) | 2021-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2021000051A2 (es) | Guías modificadas de arn para edición génica | |
CO2019007258A2 (es) | Arn guía modificados | |
PH12019502724A1 (en) | Compositions for modulating c9orf72 expression | |
CO2018004743A2 (es) | Proteínas de unión al antígeno anti-tigit y métodos para usarlas | |
MX2022003891A (es) | Anticuerpos anti-muc16 y sus usos. | |
MD3209310T2 (ro) | Compoziții care conțin tulpini bacteriene | |
MD3209381T2 (ro) | Compoziții care conțin tulpini bacteriene | |
KR20180084895A (ko) | 효소 내재화 조성물 및 방법 | |
CR20140441A (es) | Anticuerpos anti-lgr5 e inmunoconjugados | |
MX2016003636A (es) | Animales no humanos que tienen un gen de proteina reguladora de señal humanizado. | |
CO2019005992A2 (es) | Composiciones de arni de serpina1 y sus métodos de uso | |
CO7151527A2 (es) | Anticuerpos anti-cd79 b e inmunoconjugados | |
CO2022009562A2 (es) | Arn guía modificados para edición de genes | |
CL2023002358A1 (es) | Constructos de arni para inhibir la expresión de pnpla3 y sus métodos de uso | |
CR20140529A (es) | Anticuerpos e inmunoconjugados contra ly6e y métodos de uso | |
CR20150047A (es) | Anticuerpos anti-cd22 e inmunoconjugados | |
UY35582A (es) | COMPOSICIONES DE ARNi DE SERPINA1 Y SUS MÉTODOS DE USO | |
CO6690815A2 (es) | Métodos y composiciones para inmunoterapia para enfermedad neural | |
UY34636A (es) | Composiciones tópicas que comprenden fipronilo y permetrina y sus métodos de uso | |
CL2018001788A1 (es) | Composiciones y métodos para evaluar el riesgo de ocurrencia de cáncer. | |
AR106769A1 (es) | Composiciones que comprenden cepas bacterianas | |
IT201600109735A1 (it) | Biomarcatori e metodi per la diagnosi in vitro di sclerosi multipla. | |
EA202092991A1 (ru) | Модифицированные направляющие рнк, которые используются для редактирования генома | |
TH1901007589A (th) | องค์ประกอบและวิธีการสำหรับการทำให้เอนไซม์เคลื่อนเข้าภายใน | |
AR110225A1 (es) | COMPOSICIONES DE ARNi DE SERPINA1 Y SUS MÉTODOS DE USO |